TY - JOUR
T1 - Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids
AU - Pelosi, Giuseppe
AU - Pasini, Felice
AU - Fraggetta, Filippo
AU - Pastorino, Ugo
AU - Iannucci, Antonio
AU - Maisonneuve, Patrick
AU - Arrigoni, Gianluigi
AU - De Manzoni, Giovanni
AU - Bresaola, Enrica
AU - Viale, Giuseppe
PY - 2003/11/1
Y1 - 2003/11/1
N2 - Immunoreactivity for fascin, an actin-bundling protein related to cell motility, has been reported in breast, ovary, pancreas, skin, and non-small cell carcinomas, and associated with more advanced disease stage and poorer prognosis. Data on pulmonary neuroendocrine (NE) tumors, however, are lacking. We evaluated the expression of fascin by immunohistochemistry - using two different monoclonal antibodies - in surgical specimens of pulmonary NE tumors of all the diverse histological types from 128 consecutive patients recruited between 1987 and 2001, and investigated its relationship with the presence of lymph node metastases. Overall, fascin immunoreactivity was detected in 5% of 38 typical carcinoids (TC), 35% of 23 atypical carcinoids (AC), 83% of 40 large-cell neuroendocrine carcinomas (LCNEC), and 100% of 27 small-cell lung carcinomas (SCLC) (P5%) (P=0.020), and with either down-regulation or altered subcellular compartmentalization of E-cadherin (P
AB - Immunoreactivity for fascin, an actin-bundling protein related to cell motility, has been reported in breast, ovary, pancreas, skin, and non-small cell carcinomas, and associated with more advanced disease stage and poorer prognosis. Data on pulmonary neuroendocrine (NE) tumors, however, are lacking. We evaluated the expression of fascin by immunohistochemistry - using two different monoclonal antibodies - in surgical specimens of pulmonary NE tumors of all the diverse histological types from 128 consecutive patients recruited between 1987 and 2001, and investigated its relationship with the presence of lymph node metastases. Overall, fascin immunoreactivity was detected in 5% of 38 typical carcinoids (TC), 35% of 23 atypical carcinoids (AC), 83% of 40 large-cell neuroendocrine carcinomas (LCNEC), and 100% of 27 small-cell lung carcinomas (SCLC) (P5%) (P=0.020), and with either down-regulation or altered subcellular compartmentalization of E-cadherin (P
KW - Carcinoid
KW - Fascin
KW - Immunohistochemistry
KW - Lung
KW - Neuroendocrine
KW - Tumors
UR - http://www.scopus.com/inward/record.url?scp=10744221447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=10744221447&partnerID=8YFLogxK
U2 - 10.1016/S0169-5002(03)00294-0
DO - 10.1016/S0169-5002(03)00294-0
M3 - Article
C2 - 14568688
AN - SCOPUS:10744221447
VL - 42
SP - 203
EP - 213
JO - Lung Cancer
JF - Lung Cancer
SN - 0169-5002
IS - 2
ER -